Hanger announces findings of first-of-its-kind study that compares microprocessor knee models to help inform clinical-decision making

November 5, 2020

Published in the Journal of Rehabilitation and Assistive Technologies Engineering (RATE), the study reveals both differences and parities among four common MPKs

AUSTIN, Texas, Nov. 5, 2020 – Hanger, Inc. (NYSE: HNGR) today announced results of its **O**utcomes **AS**sessment and D**IS**semination (OASIS) 1 study, which evaluates the effectiveness of four common microprocessor-controlled knee (MPK) models. Outcomes in the areas of mobility, satisfaction, quality of life and injurious falls were examined for patients using: Blatchford's Orion, Freedom Innovations' Plie, Ossur's Rheo and Ottobock's C-Leg. The study is anticipated to be the first of a series that will compare a variety of orthotic and prosthetic (O&P) components across different patient groups, ultimately enhancing patient outcomes across the O&P profession.

"Hanger is committed to conducting meaningful clinical research to better serve our patients," stated James Campbell, PhD, Hanger Chief Clinical Officer. "The OASIS 1 study is significant in that we have harnessed our research capabilities to objectively measure differences across various manufacturers' devices, not just device categories, and carries the advantage of being completed and disseminated absent of potential bias due to manufacturer funding or publication. The ability to select components from various manufacturers that yield the best outcomes is critical to effective patient care."

Results found that there was a degree of parity among the four different MPK models for the sample of 602 individuals, with no differences reported in mobility or satisfaction. There was, however, a significant reduction in injurious fall rates for C-Leg and Orion users compared to injurious fall rates for patients with amputation due to diabetes or vascular disease using a non-microprocessor knee. Additionally, the study reported similar age-related changes in outcomes with each MPK.

"As the leading independent provider of orthotic and prosthetic care in the nation, Hanger is in a unique position to collect and publish previously unknown insights relating to different care plans available to clinicians," stated Hanger President and Chief Executive Officer Vinit Asar. "This clinical insight will help support professionals in making informed, unbiased decisions about patient care, and in turn, provide the best possible treatment for each individual who requires O&P services."

The OASIS series is part of a vast collection of landmark research studies already published, or in various stages of publication by Hanger Clinic's Clinical and Scientific Affairs Department, in collaboration with leading researchers, clinical, and academic institutions. Additional information on previously published research can be found here: https://hangerclinic.com/for-professionals/research-innovation/.

About Hanger, Inc. – Hanger, Inc. (NYSE: HNGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with approximately 800 locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. With nearly 160 years of clinical excellence and innovation, Hanger's vision is to lead the orthotic and prosthetic markets by providing superior patient care, outcomes, services and value. For more information on Hanger, visit www.hanger.com.

###

Krisita Burket, Hanger, Inc.
904-239-4627, kburket@hanger.com

Meghan Williams, Hanger, Inc.
512-777-3701, megwilliams@hanger.com